Atara Biotherapeutics, Inc.
NASDAQ:ATRA · NASDAQ Global Select
+$0.19 today
Vol 0.11M · Avg 1.40M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:ATRA · Revenue to Net Income
Key Ratios
Analysis
$23.1M of revenue converted into -$9.5M of net income for the selected period. Gross margin is 90.7% and net margin is -282.0%, showing how much revenue survives after costs and taxes. EPS is $-0.67, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $120.8M -6.3% | $128.9M +1404.0% | $8.6M -86.5% | $63.6M +212.6% | $20.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $21.2M +1.0% | $21.0M +136.4% | $8.9M -96.7% | $270.0M -4.3% | $282.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $99.6M -7.8% | $107.9M +34582.7% | -$313.0K +99.8% | -$206.4M +21.1% | -$261.7M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 82.4% -1.3pp | 83.7% +87.4pp | -3.7% +321.0pp | -324.7% +961.7pp | -1286.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $37.4M -75.3% | $151.5M -32.6% | $224.8M -17.5% | $272.5M -3.4% | $282.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $26.3M -34.2% | $39.9M -21.7% | $50.9M -25.3% | $68.1M -13.5% | $78.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $63.7M -66.7% | $191.4M -30.6% | $275.7M +272.1% | $74.1M -6.0% | $78.8M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.1M -58.1% | $5.1M +4.6% | $4.8M -14.6% | $5.7M -39.5% | $9.3M | $374.2M | $1.2B | $631.8M |
| EBITDA | $38.6M +151.0% | -$75.7M +71.5% | -$266.0M -19.7% | -$222.3M +32.8% | -$330.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 32.0% +90.7pp | -58.7% +3044.0pp | -3102.7% -2753.1pp | -349.6% +1276.5pp | -1626.1% | 5.6% | 46.3% | 42.0% |
| Operating Income | $35.9M +143.0% | -$83.4M +69.8% | -$276.0M +1.6% | -$280.5M +17.6% | -$340.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 29.7% +94.4pp | -64.7% +3154.8pp | -3219.5% -2778.2pp | -441.2% +1232.6pp | -1673.9% | 16.6% | 24.1% | 22.0% |
| Interest Income | $683.0K -67.6% | $2.1M -61.1% | $5.4M +77.4% | $3.1M +733.5% | $367.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $3.8M -17.8% | $4.6M -12.7% | $5.3M +1316.9% | $373.0K | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$3.1M -59.0% | -$2.0M -1782.9% | -$105.0K -100.2% | $52.2M +14129.7% | $367.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $32.7M +138.3% | -$85.4M +69.1% | -$276.1M -20.9% | -$228.3M +32.9% | -$340.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 27.1% +93.3pp | -66.2% +3154.5pp | -3220.7% -2861.6pp | -359.1% +1313.0pp | -1672.1% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $31.0K +358.3% | -$12.0K -180.0% | $15.0K +25.0% | $12.0K -73.9% | $46.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $32.7M +138.3% | -$85.4M +69.1% | -$276.1M -20.9% | -$228.3M +32.9% | -$340.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | 27.1% +93.3pp | -66.2% +3154.6pp | -3220.9% -2861.8pp | -359.1% +1313.2pp | -1672.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 +122.9% | -$11 +82.5% | -$65 -16.5% | -$56 +38.4% | -$91 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +122.5% | -$11 +82.5% | -$65 -16.5% | -$56 +38.4% | -$91 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $12.5M +67.5% | $7.5M +76.8% | $4.2M +3.8% | $4.1M +8.9% | $3.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $12.7M +69.8% | $7.5M +76.8% | $4.2M +3.8% | $4.1M +8.9% | $3.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$311.91M
Sutro Biopharma, Inc.
NASDAQ:STRO
$285.64M
MacroGenics, Inc.
NASDAQ:MGNX
$258.81M
Shattuck Labs, Inc.
NASDAQ:STTK
$233.53M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$155.72M
InflaRx N.V.
NASDAQ:IFRX
$130.09M
Champions Oncology, Inc.
NASDAQ:CSBR
$89.71M
Coya Therapeutics, Inc.
NASDAQ:COYA
$89.04M
Clene Inc.
NASDAQ:CLNN
$60.40M
Context Therapeutics Inc.
NASDAQ:CNTX
$56.66M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ATRA generate?
Atara Biotherapeutics, Inc. (ATRA) reported $120.77M of revenue in fiscal 2025.
Is ATRA profitable?
Atara Biotherapeutics, Inc. (ATRA) reported $32.69M of net income, with a net margin of 27.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.